Consequently, GSK recently announced its acquisition of 35Pharma to advance a promising GSK pulmonary hypertension drug candidate. This $950 million cash deal represents the second major move by new CEO Luke Miels. Specifically, the acquisition focuses on HS235, an experimental therapy designed to treat pulmonary hypertension. This condition currently affects over 80 million people globally and remains a life-shortening disease. Therefore, medical professionals closely watch these developments in the respiratory pipeline.

Clinical Potential of the GSK Pulmonary Hypertension Drug

Furthermore, HS235 targets patients who suffer from obesity and a specific type of heart condition. Early studies on obese mice with preserved ejection fraction showed that the drug effectively reduced fat mass. Notably, it also boosted heart function during these preclinical trials. Additionally, researchers believe that if clinical trials succeed, patients might only require an injection every four weeks. This reduced dosing frequency could significantly improve patient compliance and quality of life.

Strategic Expansion and Pipeline Growth

Simultaneously, Miels aims to counter looming patent expiries for GSK's top-selling HIV medications. This deal follows a $2.2 billion acquisition of RAPT Therapeutics earlier this year. Moreover, GSK secured global rights to kidney disease therapies from Frontier Biotechnologies just this week. These strategic bolt-on deals reflect a broader shift toward specialized therapeutic areas. Consequently, the company avoids the increasingly crowded general obesity treatment market. Instead, GSK prioritizes the downstream effects of obesity, such as liver and heart diseases.

Frequently Asked Questions

Q1: What is the primary target of the drug HS235?

HS235 targets pulmonary hypertension, specifically in patients with obesity and heart conditions like preserved ejection fraction.

Q2: How often would patients receive the HS235 injection if approved?

Clinical trials suggest the injectable drug could be administered once every four weeks or potentially even less frequently.

Q3: Why is GSK focusing on niche obesity-related diseases?

The company seeks to avoid the crowded general obesity market by focusing on downstream effects like liver, heart, and respiratory issues.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. GSK to buy 35Pharma for $950 million in CEO Miel's second major deal - ETHealthworld


2. Reuters Reporting: Prerna Bedi and Bhanvi Satija


3. GSK Strategic Pipeline Update February 2026